Robert M. Tynebor
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert M. Tynebor.
Bioorganic & Medicinal Chemistry Letters | 2011
Robert M. Tynebor; Meng-Hsin Chen; Swaminathan R. Natarajan; Edward A. O’Neill; James E. Thompson; Catherine E. Fitzgerald; Stephen J. O’Keefe; James B. Doherty
This manuscript concludes the Structure Activity Relationship (SAR) on the pyridazinone scaffold and identifies a compound with subnanomolar p38α activity and 24h coverage in the rat arthritis efficacy model.
Bioorganic & Medicinal Chemistry Letters | 2010
Robert M. Tynebor; Meng-Hsin Chen; Natarajan; Edward A. O'Neill; James E. Thompson; Catherine E. Fitzgerald; Stephen J. O'Keefe; James B. Doherty
The development and synthesis of potent p38alpha MAP kinase inhibitors containing a 2H-quinolizin-2-one platform is described. Evolution of the 2H-quinolizin-2-one series from an early lead to solving off target activity and pharmacokinetic issues is also discussed.
Synthetic Communications | 2013
Robert M. Tynebor; Elizabeth Millings
Abstract Synthesis of five membered heterocycles from an aryl tribromomethyl functional group is discussed. Exposing a tribromomethyl group to subsequent nucleophilic attacks by a 1,2-di-nucleophilic species promotes the cyclization of five membered heterocycles. Such heterocycles as oxadiazoles, thiadiazole, benzimidazole, benzothioazole, and benzoxazole were synthesized in moderate to good yields. Supplemental materials are available for this article. Go to the publishers online edition of Synthetic Communications® to view the free supplemental file. GRAPHICAL ABSTRACT
Bioorganic & Medicinal Chemistry Letters | 2010
Robert M. Tynebor; Meng-Hsin Chen; Swaminathan R. Natarajan; Edward A. O’Neill; James E. Thompson; Catherine E. Fitzgerald; Stephen J. O’Keefe; James B. Doherty
The development and synthesis of potent p38alpha MAP kinase inhibitors containing a 2H-quinolizin-2-one platform is described. Evolution of the 2H-quinolizin-2-one series from an early lead to solving off target activity and pharmacokinetic issues is also discussed.
Bioorganic & Medicinal Chemistry Letters | 2010
Robert M. Tynebor; Meng-Hsin Chen; Swaminathan R. Natarajan; Edward A. O’Neill; James E. Thompson; Catherine E. Fitzgerald; Stephen J. O’Keefe; James B. Doherty
The development and synthesis of potent p38alpha MAP kinase inhibitors containing a 2H-quinolizin-2-one platform is described. Evolution of the 2H-quinolizin-2-one series from an early lead to solving off target activity and pharmacokinetic issues is also discussed.
Archive | 2006
Sandeep A. Saggar; John T. Sisko; Thomas J. Tucker; Robert M. Tynebor; Dai-Shi Su; Neville J. Anthony
Tetrahedron Letters | 2006
Swaminathan R. Natarajan; Meng-Hsin Chen; Stephen T. Heller; Robert M. Tynebor; Ellen M. Crawford; Cui Minxiang; Han Kaizheng; Jingchao Dong; Bin Hu; Wu Hao; Shu-Hui Chen
Archive | 2006
Meng-Hsin Chen; James B. Doherty; Robert M. Tynebor
Archive | 2006
Meng-Hsin Chen; James B. Doherty; Robert M. Tynebor; Swaminathan R. Natarajan; Zhen Li; Soumya P. Sahoo
Archive | 2013
John T. Sisko; Thomas J. Tucker; Robert M. Tynebor